Several type II kinase inhibitors such as the FDA approved drugs ponatinib and sorafenib, which target RIPK1, also block the kinase activity of RIPK3 and can protect mice from TNF-induced systemic inflammatory response syndrome (SIRS) and renal ischemia-reperfusion injury (139). Here, RIPK1 is linked to systemic inflammatory response syndrome.